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plasma up to 48 h after dosing and the estimation of the elimina- 
tion half-life from plasma indicated that this parameter averages 
up to 15 hours. 
A visual inspection of the plasma concentration vs time profiles 
after oral and intravenous administration indicated that the elim- 
ination phase of glucosamine is similar after both administra- 
tion routes and thus that the absorption process of glucosamine 
through the gastrointestinal tract does not influence the drug dis- 
position. 
Conclusions: Oral administration of crystalline glucosamine sul- 
fate in the rat affords rapid and unlimited absorption of glu- 
cosamine supporting the validity of this administration route to 
obtain complete pre-systemic availability. The absolute bioavail- 
ability is in the 30% range and the pharmacokinetic pattern after 
oral administration resembles the recent human findings. 
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Aim of Study: To assess symptomatic hange after fluoroscop- 
ically guided intra-articular corticosteroid (lAST) injection in hip 
osteoarthritis (OA), and to examine dose-response and predic- 
tors of response. 
Methods: After institutional ethics approval, 120 consecutive OA 
hip patients (90 women, 30 men, median age 64 years) referred 
for lAST injection were prospectively included. Body mass index 
(BMI), WOMAC scores, conventional radiographic grade (Kell- 
gren and Lawrence scoring) and ultrasound capsular thickness 
(graded normal, mild, moderate and severe) were recorded at 
baseline. All injections were performed fluoroscopically using 40 
mg (n=75) or 80mg (n=45) of methylprednisolone and 4cc of 
0.5% bupivocaine. Repeat WOMAC scores were obtained 6 and 
12 weeks after injection. Analyses were performed on percentage 
change from baseline for WOMAC scores, with clinical 'respon- 
ders' classified as those achieving greater than 15% reduction in 
baseline pain score. 
Results: There was significant pain improvement for 40mg and 
80mg doses at 6 weeks (Z=-3.895, p<0.001 ;Z=-4.323, p<0.001 )
but only for the 80mg dose at week 12 (Z=3.164, p=0.002). Both 
the 40 and the 80mg doses demonstrated a significant stiffness 
improvement at 6 weeks (C2=14.469, df=2, p=0.001; c2=29.457, 
df=2, p<0.001), but only the 80mg dose maintained this effect at 
week 12. Only the 80mg dose showed a significant improvement 
in disability over 12 weeks (Z=-2.877, p=0.004). Clinically impor- 
tant improvement (>15%) only occurred with the 80mg dose at 
6 weeks for pain (27%), stiffness (25%) and disability (19.25%). 
Imaging findings did not relate to severity of symptoms or re- 
sponse. Lower BMI was the only predictor of response. 
Conclusion: This prospective study demonstrates for the first 
time a dose-response to lAST, with methylprednisolone 80mg 
providing a significant improvement in pain, stiffness and function 
in a large OA hip cohort. However, clinically important improve- 
ment was only evident at 6 weeks post-injection. 
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Objective: Glucosamine hydrochloride (glucosamine) and chon- 
droitin sulfate (CS) are commonly used as supplemental drugs 
for treatment of osteoarthritis (OA) and are shown to modify the 
progression and symptom of OA in clinical trials. We investigated 
the effect of long term oral administration of glucosamine and CS 
on cartilage degeneration in a guinea pig model of spontaneous 
OA. 
Methods: Glucosamine (150mg/kg) or CS (150mg/kg)-contain- 
ing foods were given to the guinea pigs for total of 12 months. The 
effects of glucosamine and CS on the knee cartilage degenera- 
tion were examined by evaluating radiographs (osteophyte forma- 
tion and osteosclerotic hanges), serum concentration of CS6S, 
CS4S, and histology compared to the controls at 3, 6, 12 months. 
Histological changes were evaluated by Modified Mankin's grad- 
ing system scored by structure, cellular abnormality and matrix 
staining. Matrix metalloproteinase III (MMP-III) staining was per- 
formed using immunohistochemistry. 
Results: There was no difference in the radiographical OA 
changes in all three groups. In biochemical analysis, there was 
no difference in the serum concentration of CS6S, CS4S and 
in the 6S/4S ratio. In contrast, there was a significant decrease 
in the score of matrix staining at 12 months in the glucosamine 
group and CS group compared to that in the control (p<0.0015, 
p<0.001). MMP-III expression was equally seen in the cartilage 
cells in all three groups and was expanded into the inner layer 
with progression of OA, being maximum at 6 months. 
Conclusion: Our results indicate that long term oral administra- 
tion of glucosamine or CS can inhibit the release and destruction 
of extracelluar matrix in the cartilage of OA by a mechanism inde- 
pendent of MMP-III expression. These results provide suggestive 
mechanism to explain the beneficial effect of glucosamine and CS 
in the prevention of articular cartilage loss in patients with OA. 
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ARTHRITIS INTERVENTION TRIAL (GAIT) 
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GAIT was a randomized double-blind placebo- and celecoxib- 
controlled trial of 1583 osteoarthritis (OA) patients designed to 
evaluate the efficacy of glucosamine, chondroitin sulfate, and 
the combination in improving OA knee pain. The primary out- 
come was defined as the proportion of patients who achieved 
a 20% improvement in the Western Ontario and McMaster Uni- 
versity Osteoarthritis Index (WOMAC) summed pain subscale 
at the end of the treatment compared to baseline. A 60.1% 
placebo response rate was observed. Table 1 compares selected 
baseline characteristics between placebo responders and non- 
responders. 
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Abstract P164 - Table 1 
Characteristic Responder Non-Responder P-value 
Sample Size 
Age (years) mean (s.d.) 
Female n (%) 
Race n (%) White 
Black 
Other 
Body Mass Index (kg/m 2) mean (s.d.) 
Duration of OA Symptoms (years) mean (s.d.) 
Acetaminophen Use (500mg tablets/day) mean (s.d.) 
ARA Functional Class n (%) Class I 
Class II 
Class III 
Kellgren & Lawrence n (%) Grade 2 
Grade 3 
Patient Global Assessment of Disease Status mean (s.d) 
Physician Global Assessment of Disease Status mean (s.d.) 
WOMAC Pain Score (mm) mean (s.d.) 
WOMAC Stiffness Score (mm) mean (s.d.) 
WOMAC Function Score (mm) mean (s.d.) 
HAQ Alternative Disability Score mean (s.d.) 
HAQ Pain Score mean (s.d.) 
SF-36 Physical Component Score mean (s.d.) 
SF-36 Mental Component Score mean (s.d.) 
162 151 
58.5 (9.5) 57.9 (10.3) 0.61 
121 (64.4) 79 (63.2) 0.83 
151 (80.3) 96 (76.8) 0.69 
21 (11.2) 18 (14.4) 
16 (8.5) 11 (8.8) 
31.8 (6.6) 32.0 (8.3) 0.75 
8.7 (8.7) 10.6 (9.5) 0.07 
1.1 (2.0) 1.4 (2.1) 0.12 
44 (23.4) 36 (28.8) 0.42 
107 (56.9) 62 (49.6) 
37 (19.7) 27 (21.6) 
113 (60.1) 66 (52.8) 0.20 
75 (39.9) 59 (47.2) 
46.2 (21.8) 50.1 (20.1) 0.11 
50.6 (17.7) 52.5 (19.1) 0.37 
236.9 (71.7) 237.4 (78.0) 0.95 
104.5 (44.2) 109.7 (40.1) 0.29 
733.9 (306.8) 813.9 (315.3) 0.03 
0.77 (0.42) 0.82 (0.42) 0.31 
53.2 (22.0) 57.9 (19.0) 0.05 
37.1 (7.7) 37.0 (9.0) 0.89 
54.0 (9.6) 52.7 (10.2) 0.24 
HAQ = Health Assessment Questionnaire; SF-36 = Medical Outcomes Study Short Form 36 
GAIT placebo responders had a shorter duration of OA symp- 
toms, lower WOMAC Function and lower HAQ Pain scores. 
Based on the variables in Table 1, we performed a logistic re- 
gression analysis to determine variables that were predictors of a 
higher placebo response rate. 
Table 2 
Variable Coefficient SE p-value 
Baseline WOMAC Function Score -0.00080 0.00038 0.036 
Duration of OA Symptoms (years) -0.0207 0.0129 0.11 
Baseline Acetaminophen Use 
(500mg tablets/day) -0.0885 0.0561 0.11 
These analyses demonstrated that higher WOMAC Function, 
longer duration of OA symptoms, and greater acetaminophen use 
are negatively associated with placebo response. 
Patients with more severe and longer duration of OA symptoms 
are less likely to be placebo responders. This may be an impor- 
tant consideration when planning OA clinical trials. 
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AN IN VITRO EVALUATION OF THE COMPATIBILITY OF 
HYLAN G-F 20 WITH FLUOROSCOPIC CONTRAST 
AGENTS USED FOR HIP INJECTIONS 
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Hylan G-F 20 is a derivatized hyaluronan based viscosupplement 
for treating pain associated with osteoarthritis of the knee. Hylan 
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Abstract P165 - Fig. 1. Changes  in G' of hylan G-F 20 contrast groups as  function of incubation time at 37°C. 
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Abstract P165 - Fig. 2. Recovery of the contrast agents after mixing with hylan G-F 20 and incubation (CZE analysis). 
